HoldingsChannel.com
| Date | Insider | Price | Amount |
|---|---|---|---|
| 11-8-2023 Insider Buy |
Asit Parikh Director |
$7.81 CAGR » |
$58,580.00 7,500 shares |
| 2-13-2023 Insider Buy |
Asit Parikh Director |
$7.73 CAGR » |
$38,660.00 5,000 shares |
| 4-11-2023 Insider Buy |
Azmi Nabulsi Chief Operating Officer |
$8.26 CAGR » |
$82,600.00 10,000 shares |
| 4-10-2023 Insider Buy |
Asit Parikh Director |
$7.55 CAGR » |
$7,550.00 1,000 shares |
| 4-6-2023 Insider Buy |
Terrie Curran President and Chief Executive |
$7.82 CAGR » |
$101,025.29 12,919 shares |
| 1-12-2023 Insider Buy |
Asit Parikh Director |
$7.00 CAGR » |
$35,000.00 5,000 shares |
| 5-13-2022 Insider Buy |
Terrie Curran President and Chief Executive |
$7.41 CAGR » |
$151,835.30 20,500 shares |
| 5-16-2022 Insider Buy |
Azmi Nabulsi Chief Operating Officer |
$8.16 CAGR » |
$163,288.00 20,000 shares |
| 5-12-2022 Insider Buy |
Asit Parikh Director |
$8.00 CAGR » |
$100,000.00 12,500 shares |
| 10-29-2019 Insider Buy |
Michael F. Cola Director |
$19.00 CAGR » |
$186,162.00 9,798 shares |
| 4-1-2020 Insider Buy |
RA CAPITAL MANAGEMENT, L.P. >10% Owner |
$24.86 CAGR » |
$2,923,641.84 117,600 shares |
| 3-31-2020 Insider Buy |
RA CAPITAL MANAGEMENT, L.P. >10% Owner |
$24.58 CAGR » |
$1,489,263.66 60,600 shares |
| 10-29-2019 Insider Buy |
Frazier Life Sciences IX, L.P. >10% Owner |
$19.00 CAGR » |
$19,999,989.00 1,052,631 shares |
| 10-29-2019 Insider Buy |
Jonathan S. Edwards Director |
$19.00 CAGR » |
$19,999,989.00 1,052,631 shares |
Also See: Institutional Holders of PHAT
Also See: SEC filings
|
Growth of $10,000.00 Without Dividends Reinvested |
||
| Start date: | 11/09/2023 | |
| End date: | 05/02/2024 | |
| Start price/share: | $7.86 | |
| End price/share: | $9.76 | |
| Dividends collected/share: | $0.00 | |
| Total return: | 24.17% | |
| Annualized Gain: | 50.71% | |
| Starting investment: | $10,000.00 | |
| Ending investment: | $12,417.00 | |
| Years: | 0.48 | |
Phathom Pharmaceuticals Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Phathom Pharmaceuticals insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding PHAT
 Free PHAT Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
|
|
|
Other companies seeing insider buying close in time to when the Phathom Pharmaceuticals Insider Buying occurred are:
Exxon Mobil Insider Buying
|
